Emergence of SGLT2 inhibitors for CKD

Hi Renukaprasad A R, Chronic kidney disease (CKD) is a serious health condition that affects 697.5 million people every year and causes 1.2 million deaths per year globally. It is characterized by a gradual loss of renal function and is a common manifestation of hypertensive and diabetics. Previously established ACE inhibitors and ARB drugs were effective in decreasing the progression of CKD, however, did not reduce its all-cause mortality. SGLT2 inhibitors have revolutionized the treatment of CKD as a promising therapeutic option by reducing the risk of progression and associated risk of all-cause mortality of CKD. Join the illustrious Dr. Bharat V. Shah in our exclusive webinar, TODAY, 6:00 PM IST onwards, to learn more about the role of SGLT2 inhibitors in battling CKD. Click to Join   India's Largest Online Community Of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*